Vaccine Against Drug-Resistant Infections: A New Hope
Summary of the Article: Improving BCG Vaccination to reduce Newborn Deaths & Combat antimicrobial resistance
This article argues that current BCG vaccination practices are suboptimal and that simple policy changes could significantly reduce newborn deaths and even help combat antimicrobial resistance (AMR). Here’s a breakdown of the key points:
The Problem:
* Low Birthweight: A meaningful percentage of babies are born underweight, notably in South Asia, increasing their vulnerability.
* Delayed BCG coverage Measurement: The WHO currently measures BCG coverage at 12 months, which doesn’t incentivize timely administration (at birth) when it’s moast effective. Healthcare workers often delay vaccination to avoid wasting doses from multi-dose vials.
* Incorrect Vaccination Technique: BCG requires intradermal administration (creating a visible scar), but many vaccinators are untrained, resulting in a low scar rate (only half in some places). Scar advancement correlates with significantly lower mortality.
* Strain Variation: Not all BCG strains are equally effective. The Danish and Japanese strains are superior in inducing “trained immunity,” while the russian strain (used in parts of Asia) offers little nonspecific protection.
* WHO Oversight: The WHO’s monitoring systems lag behind scientific evidence and don’t fully recognize the potential of BCG in reducing neonatal sepsis and AMR.
Proposed Solutions:
* WHO policy Change: The WHO should explicitly recommend BCG vaccination at birth for all babies, including preterm and underweight infants.
* Immediate Vial Opening: Vaccinators should open a BCG vial even for a single child.
* Revised Coverage Assessment: Coverage should be measured at one week,with a scar check at six weeks.
* National Program & Donor Action:
* Classify BCG as an essential at-birth vaccine.
* Train midwives, healthcare practitioners, and pharmacists in proper BCG administration.
* Reward early coverage, not just overall coverage.
* Prioritize procurement of Danish and Japanese BCG strains.
* Invest in new delivery systems (patches,oral formulations).
* Link Immunization & AMR Data: The WHO’s GLASS system should monitor how at-birth BCG vaccination reduces neonatal sepsis and deaths from drug-resistant pathogens.
* Recognize BCG’s Role in Conflict Zones: BCG vaccination is particularly crucial in conflict areas, which are breeding grounds for drug-resistant infections.
Overall Argument:
The article contends that optimizing BCG vaccination – through policy changes,improved training,and strain selection – is a cost-effective and readily achievable strategy to save newborn lives and bolster the fight against the growing threat of antimicrobial resistance. It emphasizes the need for implementation to catch up with existing scientific evidence.